Artivion, Inc. (NYSE:AORT) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System lessened its stake in shares of Artivion, Inc. (NYSE:AORT) by 3.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 62,457 shares of the company’s stock after selling 2,208 shares during the quarter. New York State Teachers Retirement System’s holdings in Artivion were worth $1,786,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of AORT. Creative Planning raised its stake in Artivion by 182.1% during the 3rd quarter. Creative Planning now owns 28,635 shares of the company’s stock valued at $762,000 after purchasing an additional 18,486 shares during the period. RiverPark Advisors LLC grew its holdings in shares of Artivion by 151.6% during the third quarter. RiverPark Advisors LLC now owns 5,387 shares of the company’s stock valued at $143,000 after buying an additional 3,246 shares in the last quarter. Quest Partners LLC raised its position in Artivion by 2,481,700.0% during the third quarter. Quest Partners LLC now owns 24,818 shares of the company’s stock valued at $661,000 after buying an additional 24,817 shares during the period. Intech Investment Management LLC lifted its stake in Artivion by 6.6% in the 3rd quarter. Intech Investment Management LLC now owns 10,530 shares of the company’s stock worth $280,000 after acquiring an additional 653 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Artivion by 28.1% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company’s stock worth $522,000 after acquiring an additional 4,295 shares during the period. 86.37% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

AORT has been the topic of several research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and issued a $34.00 target price on shares of Artivion in a report on Tuesday, January 28th. Finally, Oppenheimer lifted their price objective on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artivion currently has a consensus rating of “Buy” and a consensus price target of $31.80.

Insider Buying and Selling

In related news, VP Andrew M. Green sold 7,618 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the sale, the vice president now owns 33,503 shares of the company’s stock, valued at $1,005,090. This trade represents a 18.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Jean F. Holloway sold 8,070 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total transaction of $243,068.40. Following the completion of the transaction, the senior vice president now owns 153,862 shares of the company’s stock, valued at $4,634,323.44. This trade represents a 4.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,017 shares of company stock worth $600,007 in the last three months. Insiders own 8.10% of the company’s stock.

Artivion Stock Down 1.8 %

Shares of NYSE AORT opened at $28.29 on Friday. Artivion, Inc. has a 52-week low of $18.38 and a 52-week high of $32.33. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The business has a fifty day moving average of $29.77 and a two-hundred day moving average of $27.79. The stock has a market cap of $1.19 billion, a PE ratio of -1,414.70 and a beta of 1.75.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.